All In MedTech

Device Trial Radar · NCT07925034

PREFIX FEASIBILITY Study - PRojection & Safety Evaluation of the FIXNip Nipple Reconstruction Implant

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

5

Planned (sponsor's estimate)

Start

Nov 1, 2026

Primary completion

Feb 15, 2028

Study completion Apr 2028

Sponsor

Lead sponsor
FixNip LtdNot on our public-company list
Sponsor type
Industry
First posted
Nov 9, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Device feasibility
FDA-regulated device
Yes
Who can join
Female only, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, single center, controlled, open-label feasibility IDE clinical study enrolling patients with a history of breast cancer who have previously undergone total mastectomy with breast reconstruction and are seeking nipple reconstruction.

Conditions

  • Breast Reconstruction After Mastectomy

Interventions

  • NRI implantationDevice

    NRI implantation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Feasibility study under an Investigational Device Exemption (IDE)Time frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • MD Anderson

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.